

WAHT-KD-019
Treatment of Inflammatory Bowel Disease with Biologics (in patients over 15 years of age)

Indications for Treatment

Key Document code:	Treatment of Inflammatory Bowel Disease with Biologics (In patients over 15 years of age)	
Key Document Owner:	Helen Osinski	Senior IBD CNS
Approved by:	Medicines Safety committee	
Date of Approval:	04 th November 2019	
This is the most upto date and should be used until a revised version is in place:	4 th November 2021	

Key Amendments

Date	Amendment	Approved by

Infliximab(Remicade, Inflectra, Remsima) is licenced for use in Crohns disease and Ulcerative Colitis in children and young people aged 6-17 years and in adults.

Adalimumab (Humira) is licensed for use in Crohns disease and Ulcerative Colitis in adults.
Adalimumab (Humira, Hyrimoz) is licensed for use in Crohns disease in children aged 6-17 years.

Vedolizumab (Entyvio) is licensed for use in Crohns disease and Ulcerative colitis in adults.

Ustekinumab (Stelara) is licensed for use in Crohns disease in adult patients